Browse through our press and news section by category:

01.04.2015, Mainz (Germany)

SCHOTT Innovation Award for optimized pharma syringes systems

SCHOTT award honors successful product innovations that have proven themselves on the market

The team from SCHOTT Pharmaceutical Systems received the 2015 SCHOTT Innovation Award for its project “SCHOTT TopPac^® Polymer Syringes for Highly Viscous Drugs (HVD).” Anil Busimi (second from left), Head of Global Product Management for the Sy

Innovations on the basis of strong research and development are an important growth driver for SCHOTT. SCHOTT has been presenting its own Innovation Award since 2014 to emphasize their importance, recognize team performances, and motivate employees and interdisciplinary teams to constantly pursue innovation. “The SCHOTT Innovation Award honors top innovations that have proven themselves on the market and been accepted by our customers,” explains Dr. Frank Heinricht, Chairman of the Board of Management at SCHOTT. Standard criteria for evaluating the applications for the Innovation Award include among other aspects “benefit to customers,” “the market,” “competition” and “technology/IP.” A 6-member team from SCHOTT Pharmaceutical Systems was the winner of the 2015 SCHOTT Innovation Award for its project “SCHOTT TopPac^® - Polymer Syringe for Highly Viscous Drugs (HVD).”

Hyaluronic acid is only one example of a highly viscous substance. It is mainly used in the area of cosmetics to smoothen skin, but also to treat problems with joints or to perform eye operations (cataracts). The problem is that hyaluronic acid is often extremely viscous and therefore very difficult to inject. The innovative new design of the break-resistant TopPac^® syringes made of high-quality cyclic olefin copolymer (COC) on the other hand allows the doctor to administer the drug more safely and more comfortably for the patient, even with high actuation forces. This is made possible by optimized siliconization that ensures that the plunger of the syringe glides more smoothly. SCHOTT worked on SCHOTT TopPac^® for Highly Viscous Drugs together with a customer and now has a product platform that offers high potential in a growing segment.

SCHOTT TopPac^® is a registered trade mark of SCHOTT AG.

SCHOTT is a leading international technology group in the areas of specialty glass and glass-ceramics. The company has more than 130 years of outstanding development, materials and technology expertise and offers a broad portfolio of high-quality products. SCHOTT is an innovative enabler for many industries, including the home appliance, pharmaceutical, electronics, optics, automotive and aviation industries. SCHOTT strives to play an important part of everyone’s life and is committed to innovation and sustainable success. The group maintains a global presence with production sites and sales offices in 35 countries. With its workforce of approximately 15,400 employees, sales of 1.87 billion euros were generated in fiscal year 2013/2014. The parent company, SCHOTT AG, has its headquarters in Mainz (Germany) and is solely owned by the Carl Zeiss Foundation. As a foundation company, SCHOTT assumes special responsibility for its employees, society and the environment. www.schott.com

With a newly developed design, the break-resistant SCHOTT TopPac^® polymer syringes are also suited for use in applications that involve viscous drugs such as hyaluronic acid. This development from SCHOTT Pharmaceutical Systems has now been hono

PressRelease 034/2015

Press contact

SCHOTT AG

Christine Fuhr
Public Relations Manager

Hattenbergstraße 10
55122 Mainz

Phone: +49 6131/66-4550

E-mail
https://www.schott.com

Further information

SCHOTT AG

Salvatore Ruggiero
Vice President Marketing and Communication

Hattenbergstraße 10
55122 Mainz

Phone: +49 6131/66-4140